A longtime leader in healthcare improvement, we’re developing new ways to revolutionize the industry.
Premier submitted comments to the United States Patent and Trade Office (USPTO) and Food and Drug Administration (FDA) on a request for comments to address the rising cost of pharmaceuticals and help ensure that the patent system, while incentivizing innovation, does not also unjustifiably delay generic drug and biosimilar competition beyond that reasonably contemplated by applicable law. In its comments, Premier reflects on the legislative barriers to innovating within our current healthcare system and opportunities for action to foster innovation, competition and affordability. Specifically, Premier’s comments focus on three areas: